CH Innovations

magAssist, founded in 2017 by Dr. Xu Bozhen, is a high-tech enterprise based in Suzhou, specializing in the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular diseases. The company focuses on creating short-term to medium-term ventricular assist devices that are compatible with various blood types. Utilizing advanced fluid mechanics and magnetic suspension technology, magAssist aims to minimize incompatibility issues in patients, thereby enhancing their recovery and treatment processes. The core team consists of leading experts in artificial heart engineering, leveraging extensive experience in research and development to produce domestically manufactured devices with independent intellectual property rights.

Aldatu Biosciences Inc. is a diagnostic company focused on detecting drug resistance in antiretroviral treatments for HIV. Based in Cambridge, Massachusetts, and incorporated in 2014, Aldatu leverages its proprietary PANDAA technology, which is designed for adaptive PCR diagnostics. This innovative platform facilitates the genotyping of HIV, allowing healthcare providers to match patients with the most effective drugs, thereby enhancing treatment outcomes while reducing costs associated with HIV care. The company is dedicated to improving patient care and healthcare efficiency on a global scale, reflecting its commitment to addressing public health challenges and ensuring preparedness for emerging diseases.

Noninvasix, Inc., established in 2007, is a medical technology company based in Galveston, Texas. It develops non-invasive precision oximetry systems designed to measure oxygen sufficiency within organs and veins without the need for invasive catheters. The company's primary focus is on monitoring brain oxygenation in preterm babies within newborn intensive care units (NICUs). Noninvasix has raised over $6.8 million in funding, including a seed round in late 2021, and has been supported by grants from the NIH and DOD totaling $6 million. The company's technology has been clinically validated and is protected by a robust IP portfolio comprising 9 U.S. and 8 global patents. Noninvasix has participated in prestigious accelerator programs such as Philips Healthworks and TMCx, and its innovations have earned multiple awards.